摘要
淋巴瘤化疗相关乙型肝炎病毒(HBV)再激活的发生率及病死率均有逐年上升趋势,因此预防化疗所致的HBV再激活尤为重要。发生HBV再激活的危险性与HBV的感染、抗肿瘤药物的应用等有关。对于合并HBV慢性感染的淋巴瘤患者,化疗前应施行预防性抗病毒治疗,从而避免HBV再激活,以完成多疗程化疗,延长生命,提高生活质量。化疗前预防性抗HBV治疗得到普遍认同,本文就这一领域的研究予以综述。
In recent years,the incidence rate and mortality of lymphadenoma chemotherapy-related HBV reactivation has an ascendant tendency,thus,the prevention of chemotherapy-related HBV reactivation seems to be very important.Several studies showed that risk factors associated with HBV reactivation include hepatitis B virus（HBV）and antineoplastic agents.For the lymphoma patients with chronic HBV infection,prophylactic antiviral therapy before chemotherapy is needed,in order to avoid the re-activation of HBV,complete the multi-course chemotherapy,prolong life,and improve the quality of life.This article reviewed the progress in this field.
出处
《医学综述》
2009年第21期3256-3260,共5页
Medical Recapitulate
